Outputs (127)

Motivation to Reduce Drinking and Engagement in Alcohol Misuse Treatment in Alcohol-Related Liver Disease: A National Health Survey (2021)
Journal Article
Kann, A. E., Jepsen, P., Madsen, L., Crooks, C., Fleming, K., Christensen, A. I., Lau, C. J., West, J., & Askgaard, G. (2022). Motivation to Reduce Drinking and Engagement in Alcohol Misuse Treatment in Alcohol-Related Liver Disease: A National Health Survey. American Journal of Gastroenterology, 117(6), 918-922. https://doi.org/10.14309/ajg.0000000000001616

INTRODUCTION: The study aim was to identify predictors of motivation to reduce alcohol consumption and whether motivation predicts engagement in alcohol misuse treatment in alcohol-related liver disease (ALD). METHODS: Data from health surveys and he... Read More about Motivation to Reduce Drinking and Engagement in Alcohol Misuse Treatment in Alcohol-Related Liver Disease: A National Health Survey.

Fatigue in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Network (2021)
Journal Article
Ifesemen, O. S., McWilliams, D. F., Norton, S., Kiely, P. D. W., Young, A., & Walsh, D. A. (2022). Fatigue in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Network. Rheumatology, 61(9), 3737-3745. https://doi.org/10.1093/rheumatology/keab947

OBJECTIVES: Fatigue is a disabling symptom in people with RA. This study aims to describe the prevalence, risk factors and longitudinal course of fatigue in early RA. METHODS: Demographic, clinical, quality of life (QoL), comorbidities and laboratory... Read More about Fatigue in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Network.

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021)
Journal Article
Innes, H., Nischalke, H. D., Guha, I. N., Weiss, K. H., Irving, W., Gotthardt, D., Barnes, E., Fischer, J., Ansari, A., Rosendahl, J., Shang-Kuan, L., Marot, A., Pedergnana, V., Casper, M., Benselin, J., Lammert, F., McLauchlan, J., Lutz, P. L., Hamill, V., Mueller, S., …Buch, S. (2022). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 6(5), 1213-1226. https://doi.org/10.1002/hep4.1886

The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (M... Read More about The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.

Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England (2021)
Journal Article
West, J., Card, T. R., Bishton, M. J., Lanyon, P., Ban, L., Bythell, M., Elliss-Brookes, L., Manson, J. J., Nanduri, V., Rankin, J., Tattersall, R. S., & Crooks, C. J. (2022). Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England. Journal of Internal Medicine, 291(4), 493-504. https://doi.org/10.1111/joim.13432

Background: Haemophagocytic lymphohistiocytosis (HLH) is a rare hyper-inflammatory condition with poor outcomes. Objectives: Few population-based estimates of the incidence and survival in adults exist. We aimed to provide these data for England. Met... Read More about Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England.

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum (2021)
Journal Article
Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook, D., Stuart, D. I., Mongkolsapaya, J., Nguyen-Van-Tam, J. S., Snape, M. D., Screaton, G. R., & Com-COV2 Study Group. (2022). Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet, 399(10321), 234-236. https://doi.org/10.1016/S0140-6736%2821%2902844-0

Association Between Dietary Salt and Plasma Glucose, Insulin and Hemoglobin A1c Levels Among Type 2 Diabetes Patients in Eastern China (2021)
Journal Article
Lin, Y., Chattopadhyay, K., Yang, X., Li, J. L., Chen, Y. S., Zhou, Y., & Li, L. (2021). Association Between Dietary Salt and Plasma Glucose, Insulin and Hemoglobin A1c Levels Among Type 2 Diabetes Patients in Eastern China. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 4811-4818. https://doi.org/10.2147/DMSO.S338915

Purpose: Type 2 diabetes (T2D) is one of the major public health concerns in China. Studies on the association between dietary salt intake and the glycemic response of T2D are lacking in China. The aim was to investigate the association between the l... Read More about Association Between Dietary Salt and Plasma Glucose, Insulin and Hemoglobin A1c Levels Among Type 2 Diabetes Patients in Eastern China.

Response to ‘The role of curettage as an intervention for basal cell carcinoma’. Re. ‘Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments’: reply from the authors (2021)
Journal Article
Bath-Hextall, F. J., Thomson, J., Hogan, S., Leonardi-Bee, J., Williams, H. C., & Bath‐Hextall, F. (2022). Response to ‘The role of curettage as an intervention for basal cell carcinoma’. Re. ‘Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments’: reply from the authors. British Journal of Dermatology, 186(4), 751-752. https://doi.org/10.1111/bjd.20950

MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies (2021)
Journal Article
Hollestein, L. M., Lo, S. N., Leonardi‐Bee, J., Rosset, S., Shomron, N., Couturier, D.-L., & Gran, S. (2021). MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies. British Journal of Dermatology, 185(6), 1081-1083. https://doi.org/10.1111/bjd.20600

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial (2021)
Journal Article
Stuart, A. S. V., Shaw, R. H., Liu, X., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E. A., Collins, A. M., Darton, T., Dinesh, T., Duncan, C. J. A., England, A., Faust, S. N., Ferreira, D. M., Finn, A., Goodman, A. L., Green, C. A., Hallis, B., …Snape, M. D. (2022). Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, 399(10319), 36-49. https://doi.org/10.1016/S0140-6736%2821%2902718-5

Background: Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZen... Read More about Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial (2021)
Journal Article
Munro, A. P., Jalani, L., Comelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., Van der Klaauw, A. A., Kwok, J., Libri, V., …COV-BOOST Study Group. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 398(10318), 2258-2276. https://doi.org/10.1016/s0140-6736%2821%2902717-3

Background

Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicit... Read More about Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.